pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

370 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1156Endpoints875BioPharma Dive339BioSpace293Fierce Biotech277onclive165raps104globenewswire health73
therapy area
allOncology7345Rare Disease1825Cardiology1672Immunology1455Hematology1302Vaccines1173Pulmonology1084Psychiatry & CNS858
  • Cigna to End Coverage of GLP-1 Weight-Loss Drugs Wegovy and Zepbound for Employees Starting July 1
    Cigna announced it will stop covering GLP-1 weight-loss medications for its employee health plan, effective July 1. The decision affects drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepboun…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Rising AI battle between hospitals and insurers drives soaring medical bills, says pediatric cardiologist
    Darshak Sanghavi, a pediatric cardiologist and chief medical officer of Machinify, writes an opinion piece about an emerging AI conflict between health providers and insurers over patient records a…
    STAT · 3mo agoNegative↗ source
← prev
page 11 of 15
next →
fda recalls67
fda medwatch60
fda press38
Ophthalmology491
Pain469
Endocrinology & Metabolism466
Infectious Disease437
  • Eli Lilly warns 340B hospitals to submit claims data within five days or lose price discounts
    Eli Lilly has given roughly 50 hospitals that participate in the federal 340B drug discount program a five‑day deadline to provide comprehensive claims data. The company says that if the data are n…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Revolution Medicines reports pancreatic cancer drug daraxonrasib extends median survival to 13.2 months in second-line study
    Revolution Medicines released detailed data confirming that its experimental pancreatic cancer therapy, daraxonrasib, improved overall survival for patients with advanced disease. In the second‑lin…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Daraxonrasib shows promising pancreatic cancer results as Chinese lung therapy exceeds expectations
    The latest ASCO updates highlighted detailed data on daraxonrasib, a drug targeting pancreatic cancer, indicating encouraging efficacy signals for patients. In parallel, a lung cancer treatment de…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Servier to acquire Edgewise Therapeutics' muscular dystrophy program for up to $2.65 billion
    French pharma group Servier announced it will purchase Edgewise Therapeutics' muscular dystrophy business. The transaction is valued at up to $2.65 billion, comprising a $1.55 billion upfront cash…
    STAT · 3mo agoDealPositive↗ source
  • Eli Lilly gives hospitals five days to submit 340B claims data or lose discount pricing
    Eli Lilly has issued a notice to more than 1,000 hospitals that take part in the federal 340B drug discount program, requiring them to provide comprehensive claims data within five days. The compa…
    STAT · 3mo agoRegulatoryNegative↗ source
  • ASCO meeting highlights grief alongside cancer data, honoring late oncologist Amy Lin
    At the annual American Society of Clinical Oncology meeting, scientists presented abundant new cancer data, but this year the program also gave space to the emotional side of oncology. Outgoing pr…
    STAT · 3mo agoNeutral↗ source
  • FDA misses self-imposed deadline on electric shock device ban, prompting disability advocates' outcry
    The Food and Drug Administration did not issue a decision by the end of May as it had set for itself on whether to prohibit electrical shock devices used on people with intellectual disabilities an…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Revolution Medicines' Daraxonrasib Doubles Survival in Pancreatic Cancer Trial, Study Shows
    Results from a late-stage trial of the experimental pill daraxonrasib were presented at the American Society of Clinical Oncology meeting. The data showed that patients receiving the drug lived alm…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Summit Therapeutics' Akeso cuts death risk by 34% in Chinese lung cancer trial presented at ASCO 2026
    Summit Therapeutics reported at the ASCO 2026 meeting that its experimental drug Akeso lowered the risk of death by 34% for previously untreated lung cancer patients in China when compared with the…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Ivonescimab cuts death risk by 34% in Chinese trial for squamous NSCLC
    Data presented at the American Society of Clinical Oncology showed that ivonescimab, a bispecific antibody combining two established cancer drugs, lowered the risk of death by 34% compared with sta…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Phase 3 trial shows pre- and post-surgery hormone therapy improves outcomes for high-risk prostate cancer
    A phase 3 study called PROTEUS evaluated high‑risk, early‑stage prostate cancer patients who were scheduled for surgery. The trial compared a regimen that gave two hormone therapies before and afte…
    STAT · 3mo agoPositive readoutPositive↗ source
  • RevMed earns standing ovation at ASCO for pancreatic cancer data while Akeso faces caution
    At the American Society of Clinical Oncology meeting, RevMed captured audience attention with data on its pancreatic cancer therapy, earning a rare standing ovation. In contrast, presentations fro…
    STAT · 3mo agoNeutral↗ source
  • Ultra-low dose nivolumab shows survival benefit for head and neck cancer patients in India
    Researchers presented data at the American Society of Clinical Oncology meeting showing that an ultra‑low dose of the PD‑1 inhibitor nivolumab, given with chemotherapy, extended survival for patien…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Ivonescimab cuts death risk by one-third in Chinese lung cancer trial, adds four-month survival
    A trial in China evaluated ivonescimab combined with chemotherapy in patients newly diagnosed with advanced non-small cell lung cancer. The study was presented at the American Society of Clinical O…
    BioPharma Dive · 3mo agoPositive readoutNeutral↗ source
  • BioNTech and Pfizer present bispecific cancer data at ASCO, FDA chief notes optimism
    At the American Society of Clinical Oncology meeting, BioNTech and Pfizer highlighted early results from bispecific antibody programs aimed at lung cancer. The companies described the data as promi…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Merck touts promising ADC sacituzumab tirumotecan as potential cornerstone therapy at ASCO
    Merck highlighted a new antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), licensed from Chinese biotech Kelun-Biotech, at the ASCO meeting. The company said early clinical data have give…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • Positive data from Bristol Myers in multiple myeloma and Pfizer in lung cancer unveiled at ASCO
    At the American Society of Clinical Oncology (ASCO) meeting, Bristol Myers Squibb presented early-stage results that showed a favorable response in a multiple myeloma trial. The data suggest the in…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Replimune seeks third FDA approval attempt, Pfizer signs China deal, panel backs updated Covid vaccine
    Replimune is pursuing a third attempt to secure FDA approval for its investigational therapy, after two prior submissions did not succeed. Pfizer has entered into a new agreement to expand its pre…
    STAT · 3mo agoNeutral↗ source
  • Kenyan court halts U.S. plan for Ebola quarantine facility for Americans
    A Nairobi High Court on Friday ordered a stop to a U.S. proposal to build a quarantine center in Kenya for Americans who might have been exposed to a rare Ebola strain circulating in northeastern C…
    STAT · 3mo agoRegulatoryNegative↗ source
  • GC Therapeutics appoints former BlueRock executive Stefan Irion as chief scientific officer
    GC Therapeutics announced that Stefan Irion has joined the company as its new chief scientific officer. Irion previously served in the same capacity at BlueRock Therapeutics. Irion brings experien…
    STAT · 3mo agoNeutral↗ source
  • Acceleron veterans and Westlake back new IPF biotech Oorja Bio with $30 million Series A
    Entrepreneurs who previously brought the drug Winrevair to market have launched a new biotech, Oorja Bio, to target idiopathic pulmonary fibrosis, a hard-to-treat lung disease. The company announc…
    Endpoints · 3mo agoDealPositive↗ source
  • Full-Life Technologies secures $150M Series D financing
    Full-Life Technologies announced it has raised $150 million in a Series D financing round, comprising $110 million in the main tranche and an additional $40 million. The capital is intended to adv…
    Endpoints · 3mo agoDealNeutral↗ source
  • UK adopts tobacco-free generation law, mirroring Massachusetts policy
    The United Kingdom has passed a tobacco‑free generation law that bars retailers from selling cigarettes, vapes or nicotine pouches to anyone born on or after Jan. 1, 2009. Existing customers may co…
    STAT · 3mo agoRegulatoryPositive↗ source